NDA 020375 · Bayer Hlthcare
Climara
Estradiol · Transdermal · Estrogen
Last checked: Nov 19, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1994
Dec 22, 1994
Approved uses
3
Original approval plus efficacy supplements
Registered trials
1,701
351 Phase 3, 176 recruiting
FAERS reports
57,593
24,115 serious, 958 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, PROBABLE DEMENTIA and BREAST CANCER Estrogen-Alone Therapy Endometrial Cancer There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestogen to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated to rule out malignancy in postmenopausal women with undiagnosed, persistent or recurring abnormal genital bleeding [see Warnings and Precautions (5.2) ] . Cardiovascular Disorders and Probable Dementia The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment...
What it is approved for
From the label in effect Mar 26, 2026.
Climara is indicated for: Climara is an estrogen indicated for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) Limitations of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) Prevention of Postmenopausal Osteoporosis ( 1.4 ) Limitations of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis. 1.1 Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause 1.2 Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause Limitation of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. 1.3 Treatment of Hypoestrogenism due to Hypogonadism, Castration, or Primary Ovarian Failure 1.4 Prevention of Postmenopausal Osteoporosis Limitation of Use When prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. Consider estrogen therapy only for women at significant risk of osteoporosis.
Mechanism: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol at the receptor level. The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After...
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 5, 2001 Supplement 16 · Efficacy ReviewLetterLabel
- Apr 11, 1997 Supplement 6 · Efficacy
- Dec 22, 1994 Original approval · Type 5 - New Formulation or New Manufacturer
7 products under this application
- CLIMARA · ESTRADIOL 0.06MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2
- CLIMARA · ESTRADIOL 0.025MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2
- CLIMARA · ESTRADIOL 0.1MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2
- MENOSTAR · ESTRADIOL 0.014MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription
- CLIMARA · ESTRADIOL 0.0375MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2
- CLIMARA · ESTRADIOL 0.075MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2
- CLIMARA · ESTRADIOL 0.05MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Prescription · TE AB2
Clinical trials
Interventional ClinicalTrials.gov studies with "Estradiol" as an intervention, any sponsor and status, largest first.
- Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyPivotal-lookingActive, not recruiting
Medical Research CouncilGovernment (non-federal)
NCT00268476 · 11,992 participants · Start Jul 8, 2005 · Primary completion Mar 2026
Drug: Celecoxib; Docetaxel and 7 more · For: Prostate Cancer
Sites: Lausanne, Switzerland; Winterthur, Switzerland; Chur, Switzerland · 120 sites in all
- Short-term Effects of Transdermal Estradiol on Female COVID-19 PatientsPivotal-lookingCompleted
Istanbul University - CerrahpasaAcademic, hospital or other
NCT05774405 · 9,169 participants · Start Jul 1, 2020 · Primary completion Jul 31, 2021
Drug: Climara 0.1Mg/24Hr Transdermal System · For: COVID-19; Hormone Replacement Therapy
Sites: Istanbul, Turkey (Türkiye)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)Pivotal-lookingTerminated
Organon and CoIndustry
NCT01656434 · 3,173 participants · Start Nov 2, 2012 · Primary completion Feb 12, 2014
Drug: NOMAC-E2; NETA-EE and 2 more · For: Contraception
- Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral ContraceptivePivotal-lookingTerminated
Organon and CoIndustry
NCT05264506 · 3,055 participants · Start Feb 17, 2022 · Primary completion Jan 12, 2024
Drug: NOMAC-E2 COC · For: Contraception
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 103 sites in all
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT01178125 · 2,858 participants · Start Aug 2010 · Primary completion Jan 2013
Drug: DR-102 · For: Contraception; Female Contraception
Sites: Montgomery, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 62 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product adhesion issue5,459
- drug ineffective5,040
- headache3,312
- nausea3,167
- fatigue3,124
- off label use2,704
- hot flush2,356
- pain2,237
- diarrhoea2,071
- dizziness1,911
- breast cancer female1,833
- rash1,825
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 612 |
| 2005 | 703 |
| 2006 | 535 |
| 2007 | 1,547 |
| 2008 | 1,032 |
| 2009 | 864 |
| 2010 | 1,164 |
| 2011 | 1,184 |
| 2012 | 1,414 |
| 2013 | 1,075 |
| 2014 | 1,321 |
| 2015 | 2,351 |
| 2016 | 2,855 |
| 2017 | 2,725 |
| 2018 | 3,011 |
| 2019 | 3,511 |
| 2020 | 3,484 |
| 2021 | 3,486 |
| 2022 | 3,548 |
| 2023 | 4,070 |
| 2024 | 4,307 |
| 2025 | 6,292 |
| 2026 | 6,501 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Climara (Estradiol)
2024 spending
$3.1M
Beneficiaries
6,878
22,120 claims
Per beneficiary
$447
$13.21 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,869,463 |
| 2021 | $5,690,657 |
| 2022 | $4,658,567 |
| 2023 | $3,683,131 |
| 2024 | $3,071,054 |
Part D: Menostar (Estradiol)
2024 spending
$605K
Beneficiaries
432
1,679 claims
Per beneficiary
$1,401
$38.76 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $704,281 |
| 2021 | $685,540 |
| 2022 | $651,121 |
| 2023 | $611,837 |
| 2024 | $605,353 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systematic Review and Meta-analysis: Changes of Gut Microbiota before and after Menopause.
Yang M, Wen S, Zhang J, et al. · Dis Markers 2022 · Meta-Analysis, Systematic Review
- Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study.
Gleason CE, Dowling NM, Kara F, et al. · PLoS Med 2024 · Randomized Controlled Trial, Observational Study
- Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.
Hodis HN, Mack WJ, Henderson VW, et al. · N Engl J Med 2016 · Comparative Study, Randomized Controlled Trial
- The Effect of Sex Hormones on Joint Ligament Properties: A Systematic Review and Meta-analysis.
Gilmer G, Crasta N, Tanaka MJ · Am J Sports Med 2025 · Systematic Review, Meta-Analysis
- Effect of Soy Isoflavones on Measures of Estrogenicity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Viscardi G, Back S, Ahmed A, et al. · Adv Nutr 2025 · Systematic Review, Meta-Analysis
- Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety.
Oliveira Amador WF, Saraiva CA, Ruelas MG, et al. · Eur J Obstet Gynecol Reprod Biol 2025 · Network Meta-Analysis, Systematic Review
Sponsor: Bayer · Also marketed as Menostar
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.